Beijing Hope Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China and facing the world. The main business is R&D, production and sales of APIs and APIs, import and export trade, R&D of new pharmaceutical preparations and new drug registration. We have an R&D center in Beijing, a pharmaceutical intermediate production base in Hebei and Zhejiang, and a GMP-certified API production base in Shandong.
*The following content is generated by AI and is for reference only.
Agomelatine is a novel antidepressant agent with a unique mechanism of action that distinguishes it from conventional treatments like selective serotonin reuptake inhibitors or tricyclic antidepressants. Chemically, its molecular formula is C15H20N2O, and it is identified by the CAS number 96238-28-7. Structurally, it functions as an agonist at melatonin MT1 and MT2 receptors while acting as an antagonist at the serotonin 5-HT2C receptor. This dual activity allows Agomelatine to effectively reset circadian rhythms and improve sleep quality, which are often disrupted in patients suffering from major depressive disorder. By restoring normal sleep-wake cycles, the drug helps alleviate core depressive symptoms such as insomnia, fatigue, and anxiety, leading to an overall improvement in mood and daily functioning.
Clinically, Agomelatine is primarily indicated for the treatment of major depressive episodes in adults. It is particularly valued for its ability to rapidly improve sleep architecture without causing sexual dysfunction, weight gain, or significant sedation, side effects commonly associated with other antidepressants. The drug is available in various oral tablet strengths, typically ranging from 25 mg to 50 mg, and is usually administered once daily at bedtime. While generally well-tolerated, monitoring of liver function is recommended during the initial months of therapy due to rare cases of hepatotoxicity reported in clinical studies. Its non-sedating profile during the day makes it suitable for patients who require full cognitive alertness for work or driving. As a result, Agomelatine represents a significant advancement in psychopharmacology, offering a targeted approach to treating depression by addressing both mood regulation and circadian rhythm disturbances simultaneously. Ongoing research continues to explore its potential efficacy in other psychiatric conditions involving sleep dysregulation.